Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX Electrochemotherapy in Pancreatic Adenocarcinoma
NCT02592395Phase 1Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Oct 2015
- Primary completion
- Oct 2017
01
Overview
Phase 1, open-label, single-arm trial, sponsored by UTHealth Houston. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Planned start Oct 2015; status: withdrawn.
Beyond the preview
Go deeper on NCT02592395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592395.